Table 1. . Patient characteristics and treatment.
| Patient | Gender/age (y) | Histology/tumor location | Initial therapy | First salvage therapy | Second salvage therapy | Dabrafenib Salvage therapy | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Surgery | Radiotherapy | Surgery | Radiotherapy | Chemotherapy (cycles) | Surgery | Radiotherapy | Chemotherapy (cycles) | Response | PFS (months) | OS (months) | |||
| 1 | F/26 | Gr1/frontal | STR | 54 Gy | – | – | TMZ (6) | – | – | – | SD | 4 | 6 |
| 2 | M/34 | Gr1/frontal | GTR | – | STR | 54 Gy | – | – | – | TMZ (4) | SD | 7 | 12 |
| 3 | M/45 | Gr1/temporal | GTR | – | – | 54 Gy | – | – | – | TMZ (3) | PR | 10 | 16 |
F: Female; GTR: Gross total resection; M: Male; OS: Overall survival from onset of dabrafenib; PFS: Progression-free survival; PR: Partial response; SD: Stable disease; STR: Subtotal resection; TMZ: Temozolomide.